Biocon Completes Phase I Trial For Lantus Biosimilar, As Speculation Builds On Deal For Oral Insulin
This article was originally published in PharmAsia News
Executive Summary
A steadily developing pipeline – including a biosimilar of Sanofi’s blockbuster diabetes therapy Lantus – is starting to bear fruit. Meanwhile, speculation is building that Biocon is close to partnering its oral insulin IN-105, with Bristol-Myers Squibb as a rumored suitor.